600 related articles for article (PubMed ID: 11593415)
1. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer.
Chen X; Thakkar H; Tyan F; Gim S; Robinson H; Lee C; Pandey SK; Nwokorie C; Onwudiwe N; Srivastava RK
Oncogene; 2001 Sep; 20(42):6073-83. PubMed ID: 11593415
[TBL] [Abstract][Full Text] [Related]
2. Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance.
Thakkar H; Chen X; Tyan F; Gim S; Robinson H; Lee C; Pandey SK; Nwokorie C; Onwudiwe N; Srivastava RK
J Biol Chem; 2001 Oct; 276(42):38361-9. PubMed ID: 11461904
[TBL] [Abstract][Full Text] [Related]
3. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells.
Kandasamy K; Srivastava RK
Cancer Res; 2002 Sep; 62(17):4929-37. PubMed ID: 12208743
[TBL] [Abstract][Full Text] [Related]
4. Caspase-8 activation is necessary but not sufficient for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in the prostatic carcinoma cell line LNCaP.
Rokhlin OW; Guseva NV; Tagiyev AF; Glover RA; Cohen MB
Prostate; 2002 Jun; 52(1):1-11. PubMed ID: 11992615
[TBL] [Abstract][Full Text] [Related]
5. eNOS protects prostate cancer cells from TRAIL-induced apoptosis.
Tong X; Li H
Cancer Lett; 2004 Jul; 210(1):63-71. PubMed ID: 15172122
[TBL] [Abstract][Full Text] [Related]
6. Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-kappaB activation and cFLIP(L) up-regulation.
Bortul R; Tazzari PL; Cappellini A; Tabellini G; Billi AM; Bareggi R; Manzoli L; Cocco L; Martelli AM
Leukemia; 2003 Feb; 17(2):379-89. PubMed ID: 12592338
[TBL] [Abstract][Full Text] [Related]
7. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
Ravi R; Bedi A
Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
[TBL] [Abstract][Full Text] [Related]
8. Regulation of sensitivity to TRAIL by the PTEN tumor suppressor.
Whang YE; Yuan XJ; Liu Y; Majumder S; Lewis TD
Vitam Horm; 2004; 67():409-26. PubMed ID: 15110188
[TBL] [Abstract][Full Text] [Related]
9. TRAIL-induced apoptosis in human vascular endothelium is regulated by phosphatidylinositol 3-kinase/Akt through the short form of cellular FLIP and Bcl-2.
Alladina SJ; Song JH; Davidge ST; Hao C; Easton AS
J Vasc Res; 2005; 42(4):337-47. PubMed ID: 15985761
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of phosphatidylinositol-3/Akt-kinase inhibition on apoptotic sensitization to cytokines in LNCaP and PCc-3 prostate cancer cells.
Beresford SA; Davies MA; Gallick GE; Donato NJ
J Interferon Cytokine Res; 2001 May; 21(5):313-22. PubMed ID: 11429162
[TBL] [Abstract][Full Text] [Related]
11. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2.
Munshi A; Pappas G; Honda T; McDonnell TJ; Younes A; Li Y; Meyn RE
Oncogene; 2001 Jun; 20(29):3757-65. PubMed ID: 11439339
[TBL] [Abstract][Full Text] [Related]
12. Mifepristone pretreatment overcomes resistance of prostate cancer cells to tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL).
Eid MA; Lewis RW; Kumar MV
Mol Cancer Ther; 2002 Aug; 1(10):831-40. PubMed ID: 12492116
[TBL] [Abstract][Full Text] [Related]
13. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis.
Nesterov A; Lu X; Johnson M; Miller GJ; Ivashchenko Y; Kraft AS
J Biol Chem; 2001 Apr; 276(14):10767-74. PubMed ID: 11278284
[TBL] [Abstract][Full Text] [Related]
14. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
[TBL] [Abstract][Full Text] [Related]
15. Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells.
Oka N; Nakahara S; Takenaka Y; Fukumori T; Hogan V; Kanayama HO; Yanagawa T; Raz A
Cancer Res; 2005 Sep; 65(17):7546-53. PubMed ID: 16140916
[TBL] [Abstract][Full Text] [Related]
16. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
Martelli AM; Tazzari PL; Tabellini G; Bortul R; Billi AM; Manzoli L; Ruggeri A; Conte R; Cocco L
Leukemia; 2003 Sep; 17(9):1794-805. PubMed ID: 12970779
[TBL] [Abstract][Full Text] [Related]
17. Role of phosphatidylinositol-3 kinase/Akt pathway in bladder cancer cell apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand.
Oka N; Tanimoto S; Taue R; Nakatsuji H; Kishimoto T; Izaki H; Fukumori T; Takahashi M; Nishitani M; Kanayama HO
Cancer Sci; 2006 Oct; 97(10):1093-8. PubMed ID: 16984382
[TBL] [Abstract][Full Text] [Related]
18. TRAIL-DISC formation is androgen-dependent in the human prostatic carcinoma cell line LNCaP.
Rokhlin OW; Taghiyev AF; Guseva NV; Glover RA; Syrbu SI; Cohen MB
Cancer Biol Ther; 2002; 1(6):631-7. PubMed ID: 12642685
[TBL] [Abstract][Full Text] [Related]
19. Ectopic expression of Bcl-2 and Bcl-xL inhibits apoptosis induced by TNF-related apoptosis-inducing ligand (TRAIL) through suppression of caspases-8, 7, and 3 and BID cleavage in human acute myelogenous leukemia cell line HL-60.
Lamothe B; Aggarwal BB
J Interferon Cytokine Res; 2002 Feb; 22(2):269-79. PubMed ID: 11911810
[TBL] [Abstract][Full Text] [Related]
20. Resistance of mitochondrial DNA-deficient cells to TRAIL: role of Bax in TRAIL-induced apoptosis.
Kim JY; Kim YH; Chang I; Kim S; Pak YK; Oh BH; Yagita H; Jung YK; Oh YJ; Lee MS
Oncogene; 2002 May; 21(20):3139-48. PubMed ID: 12082629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]